Last reviewed · How we verify
Intravenous Antibiotic — Competitive Intelligence Brief
phase 3
Infectious Disease
Small molecule
Live · refreshed every 30 min
Target snapshot
Intravenous Antibiotic (Intravenous Antibiotic) — The George Institute. An intravenous antibiotic that inhibits bacterial protein synthesis or cell wall formation to treat infections.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intravenous Antibiotic TARGET | Intravenous Antibiotic | The George Institute | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intravenous Antibiotic CI watch — RSS
- Intravenous Antibiotic CI watch — Atom
- Intravenous Antibiotic CI watch — JSON
- Intravenous Antibiotic alone — RSS
Cite this brief
Drug Landscape (2026). Intravenous Antibiotic — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-antibiotic. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab